Female Hormones, 5-HT2A Receptors, and Psychedelics

Female hormones affect binding at the 5-HT2A receptor. Does this mean there is a uniquely female entourage effect with psychedelics?


The potential of psychedelics for treating mental illness and improving everyday lives continues to be an area of interest for researchers and people from all walks of life. Also, the health needs and concerns of women are coming to the forefront as areas needing particular attention when studying psychedelics.

PSR recently published two articles that are opening up the conversation about women and psychedelics; Women and Psychedelics: The Big Picture and Psychedelics and Women’s Health. As part of these female-focused articles, PSR is posing the overarching question, is there a female entourage effect? This article will help answer that question by taking a closer look at the interaction between female hormones and the serotonin 5-HT2A receptor, which is responsible for the psychedelic effect. Extrapolating this information to what is known about how psychedelics work, will provide additional insight on the entourage effect in women.

What is the Entourage Effect?

PSR has published articles discussing the entourage effect in magic mushrooms and toad secretions, which get into more of the details about this phenomenon. Briefly, the term entourage effect came out of medical marijuana research. It describes the compounds in cannabis working in synergy to produce an overall effect.

For example, as far back as 1974, researchers observed in humans and animals that the effects of marijuana were 2 to 4 times greater than what would be expected from THC alone1 (THC, aka tetrahydrocannabinol or ∆9-THC, is the main psychoactive component in marijuana). The authors of this study stated, “It is suggested that there may be potentiation of the effects of ∆9-THC by other substances present in these marihuana samples.” More recently, a 2011 article published in British Journal of Pharmacology provides a comprehensive review of the science of cannabis synergy at the time.2

The main takeaway is that it is critical to consider the chemical variability in natural compounds in pharmaceutical research. Understanding individual chemicals is important. Still, there is much more to be learned from examining how they work together and at serotonin receptors in the brain, such as 5-HT2A. And to the point, female hormones add another layer of complexity to the equation by exerting their effects on these receptors.

The Relationship Between Female Hormones and the 5-HT2A Receptor

Here are a few examples from the literature showing the intriguing interactions between female hormones and the serotonin 5-HT2A receptor.

  • Research has shown that estrogen increases the density of 5-HT2A binding sites in the brain, particularly in the anterior frontal, cingulate, and primary olfactory cortex, and the nucleus accumbens, areas of the brain are responsible for controlling mood, mental state, emotion, cognition, and behavior.3 These observations explain why drugs that block 5-HT2A receptors (e.g., fluoxetine) and estrogen therapy can be effective for treating the symptoms of premenstrual syndrome. Intriguingly, this relationship between estrogen levels and 5-HT2A binding sites may also give clues to the gender differences seen in schizophrenia and depression, i.e., women are diagnosed with these conditions more often than men.
  • In a 2000 study, researchers found that estradiol (one of the three types of estrogen in women) combined with progesterone increased the binding potential of 5-HT2A receptors in the cerebral cortex of post-menopausal women.4
  • Research indicates that that disruption of estrogen levels during menopause may lead to dysregulation of the BDNF-5-HT2A signaling pathway in the brain and causes weakened synaptic plasticity.5 The authors say that these changes predispose the brain to be susceptible to depression.
  • A 2005 review article in BMC Women’s Health integrated information from studies in endocrinology, molecular biology, neuroscience, and epidemiology.6 Their findings indicated that serotonin might mediate the effects of estrogen. The authors stated, “We hypothesize that some of the physiological effects attributed to estrogen may be a consequence of estrogen-related changes in serotonin efficacy and receptor distribution.”
  • In rats, estradiol, in combination with a low dose of progesterone, increased 5-HT2A receptor mRNA gene expression in the CA2 region circuitry of the ventral hippocampus by 43% 7 (the hippocampus in the brain is important for short-term, long-term, and spatial memory). Estrogen combined with a higher dose of progesterone increased the expression of the gene by 84% in the CA1 region. Interestingly, mRNA expression in the frontal cortex was not affected by the hormones.

The studies above represent just a fraction of the scientific information investigating the effects of female hormones on one type of serotonin receptor. There are 13 more serotonin receptors in this family,8 which may have a variety of responses to female hormones (as well as a deficiency or lack of the hormones). In addition to this complexity, consider how allosteric modulation of serotonin receptors may influence the effects of estrogen, progesterone, and psychedelics.

What Does This Mean for the Effects Psychedelics Have on Women?

Scientists know that psychedelics such as psilocybin elicit their effects primarily via the serotonin 5-HT2A receptor.9 The findings from the studies above indicate that the presence, absence, and combinations of female hormones affect binding to 5-HT2A in a variety of ways. Therefore, it is feasible that the entourage effect of psychedelic compounds is different in women. Additional research into the effects of psychedelics in the unique environment of the female body would start to unravel the mystery.

Barb Bauer Headshot

Barb is the former Editor and one of the founders of Psychedelic Science Review. She is currently a contributing writer. Her goal is making accurate and concise psychedelic science research assessable so that researchers and private citizens can make informed decisions.


Notify of

Newest Most Voted
Inline Feedbacks
View all comments
4 years ago

This is simply fascinating. I hope I live long enough to see psychedelic therapy used as a first step, rather than last or never. On top of that I also believe that these treatments should be completely not-for-profit. Everyone should have access and knowledge! Gone are the days when most people simply just wanted to make the world a better place. Changing the world for the better is worth more than all the money and wealth that will ever exist.

3 years ago

Fantastic article!

3 years ago

I microdosed lsd in combination with the Depo-provera progesterone injection for 10 months. By the end, I had lost ⅔ of my hair. LSD produces DHT, which causes female pattern baldness. Just a warning.

2 years ago

Last year, I used psilocybin for the first time (in VERY high doses) to successfully treat depression, migraines, PTSD symptoms, chronic fatigue, and GI issues (by using the mushrooms alongside a food cleanse of sorts to “reset” my microbiome and facilitate long term dietary changes). Almost immediately afterward, I had my first accidental pregnancy (I wasn’t on birth control but we were using condoms) … both my partner and I are in our thirties, no history of pregnancy. We’ve been half-joking that all the mushrooms made me ridiculously fertile and I really think there should be more research in this… Read more »

Last edited 2 years ago by Meghan
2 years ago

My period was late by 2-3 weeks and I was not feeling very good overall. An intermediate dose of cubensis (it was my first time) gave me an immense good trip and a few hours later, as the effects were washing off, I started having my period. It could have been coincidence too but deep down, I feel certain the mushrooms helped.
I am looking forward to seeing more scientific studies looking into this topic.

Ilana Krisch
2 years ago

Is there any research on the effects of Psychedelics on women with polycystic ovary syndrome?

Graham Falzon
2 years ago

Recently i was helping a friend going through menopause with microdosing d,m,t.

1 0.15mg dose was enough to stop the symptoms of menopause for 3 days sometimes longer.

cognitive skills improved and overall REM sleep was 3 hours longer then without. sleep apnea improved slightly also with 50% reduction in breathing struggles

1 year ago

Thanks for exploring and sharing this new branches of knowledge! I have a specific consult in which I hope you can help me: is there any collateral effect on psychedelic use with the subcutaneous impianth for contraception?

1 year ago

Fascinating. I hope these estrogen-psilocybin connection studies continue. My experience: I have gone through menopause & was without menses for at least a year. No other symptoms either such as hot flashes. I got through menopause pretty easily btw using DHEA & Progesterone. I wasn’t on any prescription hormone therapy ever. To the point- I micro dosed psilocybin for ten days & had a normal (pre menopause normal!) menstrual cycle for 5 days. It was the strangest thing. It’s been 3 months since I micro dosed & I haven’t had menses nor spotting… nothing. ????????‍♀️

  1. Carlini EA, Karniol IG, Renault PF, Schuster CR. Effects of Marihuana in Laboratory Animals and in Man. British Journal of Pharmacology. 1974;50(2):299-309. doi:10.1111/j.1476-5381.1974.tb08576.x
  2. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology. 2011;163(7):1344-1364. doi:10.1111/j.1476-5381.2011.01238.x
  3. Sumner BEH, Fink G. Estrogen increases the density of 5-Hydroxytryptamine2A receptors in cerebral cortex and nucleus accumbens in the female rat. The Journal of Steroid Biochemistry and Molecular Biology. 1995;54(1):15-20. doi:10.1016/0960-0760(95)00075-B
  4. Moses EL, Drevets WC, Smith G, et al. Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. Biological Psychiatry. 2000;48(8):854-860. doi:10.1016/S0006-3223(00)00967-7
  5. Chhibber A, Woody SK, Rumi MAK, Soares MJ, Zhao L. Estrogen receptor β deficiency impairs BDNF–5-HT2A signaling in the hippocampus of female brain: a possible mechanism for menopausal depression. Psychoneuroendocrinology. 2017;82:107-116. doi:10.1016/j.psyneuen.2017.05.016
  6. Rybaczyk LA, Bashaw MJ, Pathak DR, Moody SM, Gilders RM, Holzschu DL. An overlooked connection: serotonergic mediation of estrogen-related physiology and pathology. BMC Womens Health. 2005;5:12. doi:10.1186/1472-6874-5-12
  7. Birzniece V, Johansson I-M, Wang M-D, Bäckström T, Olsson T. Ovarian hormone effects on 5-hydroxytryptamine(2A) and 5-hydroxytryptamine(2C) receptor mRNA expression in the ventral hippocampus and frontal cortex of female rats. Neurosci Lett. 2002;319(3):157-161. doi:10.1016/s0304-3940(01)02570-8
  8. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38(8):1083-1152. doi:10.1016/S0028-3908(99)00010-6
  9. Madsen MK, Fisher PM, Burmester D, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. January 2019:1. doi:10.1038/s41386-019-0324-9